Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-Sensitive Prostate Cancer

Interventions

BIOLOGICAL: PROSTVAC-V
BIOLOGICAL: PROSTVAC-F
DRUG: Nivolumab
DRUG: Ipilimumab
BIOLOGICAL: Neoantigen DNA vaccine
DEVICE: TriGrid Delivery System
PROCEDURE: Tumor biopsy
PROCEDURE: Peripheral blood
PROCEDURE: Fecal samples
PROCEDURE: Leukapheresis

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]